BRIEF-MediciNova Announces Presentation Of SPRINT-MS Phase 2b Trial Of MN-166 (Ibudilast)

* MEDICINOVA ANNOUNCES THE PRESENTATION OF THE SPRINT-MS PHASE 2B TRIAL OF MN-166 (IBUDILAST) IN PROGRESSIVE MS AT THE AMERICAN ACADEMY OF NEUROLOGY (AAN) 70TH ANNUAL MEETING PLENARY SESSION WITH ADDITIONAL IMAGING DATA